Acadia Pharmaceuticals
ACAD
162 hedge funds and large institutions have $2.33B invested in Acadia Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 57 reducing their positions, and 20 closing their positions.
1,000% more call options, than puts
Call options by funds: $243M | Put options by funds: $22.1M
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
20% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 20
8% more capital invested
Capital invested by funds: $2.16B → $2.33B (+$169M)
1% more funds holding
Funds holding: 160 → 162 (+2)
12% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$41.3M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$30.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$15.9M |
| 4 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
+$13.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$52.1M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$25.1M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$16.9M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$15M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$13.3M |
ACAD Hedge Fund Activity: Q3 2014 in Review
162 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2014, worth a combined $2.33B — up 7.8% from $2.16B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ACAD positions and 20 closed out — a net gain of 4 holders — while 50 added to existing stakes and 57 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $41.3M. The largest seller was Westfield Capital Management, exiting entirely with an estimated $52.1M sold.
- 162 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2014, up from 160 in Q2 2014.
- Funds reported $2.33B of Acadia Pharmaceuticals stock for Q3 2014, up 7.8% quarter-over-quarter.
- 24 funds opened new Acadia Pharmaceuticals positions in Q3 2014 and 20 closed out, a net change of +4 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2014 was Bank of New York Mellon, an estimated $41.3M added.
- The largest Acadia Pharmaceuticals seller in Q3 2014 was Westfield Capital Management, an estimated $52.1M sold.
Based on aggregated 13F filings for Q3 2014.